XRTX - יחס חוב להיוון בספרים XORTX Therapeutics Inc

The historical debt-to-book capitalization ratio for XORTX Therapeutics Inc. (XRTX) demonstrates volatility, as patent battles with industry behemoths create risks. This trend reflects the prolonged formation of distribution chains within the renal therapy sector. The value is currently held at 0.00, while the high pricing power of XORTX Therapeutics Inc. (XRTX) is based on unique proprietary forms of oxypurinol for the treatment of polycystic kidney disease.

XORTX Therapeutics Inc. (XRTX) is developing complex drugs for the treatment of rare kidney diseases within a strictly regulated environment. This ratio compares the volume of borrowed funds to equity, measuring the business's level of financial autonomy. Investors use this balance to assess the company's resilience to potential share dilution. Sharp spikes in the total debt-to-equity ratio signal a critical overheating of the debt load. Monitoring this metric allows for the timely identification of solvency risks.